Comprehensive evaluation of a novel nuclear factor-κB inhibitor, quinoclamine, by transcriptomic analysis

British Journal of Pharmacology

Volumn 157, Issue 5, 2009, Pages 746-756

  Cheng, W Y ^a   Lien, J C ^a   Hsiang, C Y ^a   Wu, S L ^a   Li, C C ^a   Lo, H Y ^a   Chen, J C ^a   Chiang, S Y ^a   Liang, J A ^b   Ho, T Y ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cell cycle; Microarray; Nuclear factor B; Quinoclamine; UDP glucuronosyltransferases

Indexed keywords

GLUCURONOSYLTRANSFERASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; QUINOCLAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG INHIBITION; GENE CONTROL; GENE TRANSLOCATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSCRIPTOMICS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GLUCURONOSYLTRANSFERASE; HUMANS; I-KAPPA B PROTEINS; NAPHTHOQUINONES; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN TRANSPORT; TRANSCRIPTION FACTOR RELA; TRANSFECTION;

EID: 70350139869     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00223.x     Document Type: Article

References (49)

1. Aggarwal BB, Shishodia S (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
2. Anazawa Y, Arakawa H, Nakagawa H, Nakamura Y (2004). Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway. Oncogene 23: 7621-7627. (Pubitemid 39424920)
3. Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE (2000). Role of the IκB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol 20: 5381-5391. (Pubitemid 30482876)
4. Bae KA, Choung SY (1996). Differentiation inducing effects of 2-chloro-3-arnino-l,4-naphthoquinone on human leukemia HL-60. Biol Pharm Bull 19: 824-827. (Pubitemid 26243233)
5. Barnes PJ, Karin M (1997). Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071. (Pubitemid 27163860)
6. Cheng WY, Wu SL, Hsiang CY, Li CC, Lai TY, Lo HY et al. (2008). Relationship between San-Huang-Xie-Xin-Tang and its herbal components on the gene expression profiles in HepG2 cells. Am J Chin Med 36: 783-797.
7. Furstenberger G, Berry DL, Sorg B, Marks F (1981). Skin tumor promotion by phorbol ester is a two-stage process. Proc Natl Acad Sci USA 78: 7722-7726. (Pubitemid 12186634)
8. Garg A, Aggarwal BB (2002). Nuclear transcription factor-KB as a target for cancer drug development. Leukemia 16: 1053-1068. (Pubitemid 34618844)
9. Gerhold D, Lu M, Xu J, Austin C, Caskey CT, Rushmore T (2001). Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol Genomics 5: 161-170. (Pubitemid 33675213)
10. Gunther EC, Stone DJ, Gerwien RW, Bento P, Heyes MP (2003). Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc Natl Acad Sci USA 100: 9608-9613.
11. Gyuris J, Golemis E, Chertkov H, Brent R (1993). Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75: 791-803. (Pubitemid 23346376)
12. Ho TY, Chen YS, Hsiang CY (2007). Noninvasive nuclear factor-κB bioluminescence imaging for the assessment of host-biomaterial interaction in transgenic mice. Biomaterials 28: 4370-4377.
13. Hsiang CY, Wu SL, Ho TY (2005). Morin inhibits 12-0tetradecanoylphorbol- 13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression. Biochem Pharmacol 69: 1603-1611.
14. Hsiang CY, Wu SL, Chen JC, Lo HY, Li CC, Chiang SY et al. (2007). Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-KB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. Toxicol Lett 171: 78-86.
15. Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK, Pan MH (2004a). Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem 52: 6330-6337.
16. Hsu YL, Kuo PL, Lin CC (2004b). Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci 75: 2303-2316. (Pubitemid 39180039)
17. Ichikawa H, Aggarwal BB (2006). Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB Iigand and by tumor cells by suppressing nuclear factor-kappaB activation. Clin Cancer Res 12: 662-668. (Pubitemid 43166162)
18. Ishiguro K, Ando T, Maeda O, Ohmiya N, Niwa Y, Kadomatsu K et al. (2007). Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun 362: 218-223. (Pubitemid 47296314)
19. Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X et al. (2002). GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin Bl and is independent of p38 kinase activity. Oncogene 21: 8696-8704. (Pubitemid 36132390)
20. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG (2001). NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12: 73-90. (Pubitemid 32294588)
21. Kapadia GJ, Azuine MA, Balasubramanian V, Sridhar R (2001). Aminonaphthoquinones - a novel class of compounds with potent antimalarial activity against Plasmodium falciparum. Pliarmacol Res 43: 363-367.
22. Karin M (2006). Nuclear factor-κB in cancer development and progression. Nature 441: 431-436.
23. Karin M, Greten FR (2005). NF-kappaB: linking Inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759. (Pubitemid 41400849)
24. Kiang TK, Ensom MH, Chang TK (2005). UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106: 97-132.
25. Kim HJ, Hawke N, Baldwin AS (2006). NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 13: 738-747.
26. Kwon H, Choung SY (1997). Induction of differentiation of U-937 cells by 2-chloro-3-amino-l,4-naphthoquinone. Res Commun Mol Pathol Pharmacol 97: 215-227. (Pubitemid 27430548)
27. Lien JC, Huang LJ, Wang JP, Teng CM, Lee KH, Kuo SC (1997). Synthesis and antiplatelet, antiinflammatory, and antiallergic activities of 2-substituted 3-chloro-l,4-naphthoquinone derivatives. Bioorg Med Chem 5: 2111-2120.
28. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A et al. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7: 255-269. (Pubitemid 27358064)
29. Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H et al. (2008). Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother Res 22: 407-415.
30. Nair A, Venkatraman M, Maliekal TT, Nair B, Karunagaran D (2003). NF-κB IS constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22: 50-58. (Pubitemid 36152883)
31. Okamoto K, Kitabayashi I, Taya Y (2006). KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. Biochem Biophys Res Commun 351: 216-222.
32. Ouzzine M, Barré L, Netter P, Magdalou J, Fournel-Gigleux S (2003). The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation. Drug Metab Rev 35: 287-303. (Pubitemid 38018108)
33. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (1992). Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971.
34. Pahl HL (1999). Activators and target genes of Re1/NF-κB transcription factors. Oncogene 18: 6853-6866.
35. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ (1997). Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275: 523-527. (Pubitemid 27051906)
36. Rahman KW, Sarkar FH (2005). Inhibition of nuclear translocation of nuclear factor-kappaB contributes to 3,3'-diindolylmethaneinduced apoptosis in breast cancer cells. Cancer Res 65: 364-371.
37. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB (2006). Plumbagin (5-hydroxy-2-methyl-l,4-naphthoquinone) suppresses NF-κB activation and NF-κB-regulated gene products through modulation of p65 and IκB-α kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 281: 17023-17033. (Pubitemid 43909506)
38. Sato H, Ishida S, Toda K, Matsuda R, Hayashi Y, Shigetaka M et al. (2005). New approaches to mechanism analysis for drug discovery using DNA microarray data combined with KeyMolnet. Curr Drug Discov Technol 2: 89-98. (Pubitemid 40943979)
39. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. (2003). Cytoscape: a software environment for integrated models of biomolecular Interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)
40. Sidorova YA, Grishanova AY (2004). Dose- and time-dependent effects of menadione on enzymes of xenobiotic metabolism in rat liver. Bull Exp Biol Med 137: 231-234.
41. Smyth GK (2005). Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, pp. 397-420.
42. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM et al. (1997). Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960. (Pubitemid 28022831)
43. Ueda Y, Richmond A (2006). NF-κB activation in melanoma. Pigment Cell Res 19: 112-124.
44. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999). The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127. (Pubitemid 29045184)
45. Wu JT, Kral JG (2005). The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158-169. (Pubitemid 40094658)
46. Xia H, Qi H, Li Y, Pel J, Barton J, Blackstad M et al. (2002). LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21: 1233-1241. (Pubitemid 34185240)
47. Yu SM, Wu JF, Lin TL, Kuo SC (1997). Inhibition of nitric oxide synthase expression by PPM-18, a novel anti-inflammatory agent, in vitro and in vivo. Biochem J 328: 363-369.
48. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, Ijiri K et al. (2004). NF-κB-mediated repression of growth arrest- and DNA-damageinducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci USA 101: 13618-13623.
49. Zhang B, Kirov S, Snoddy J (2005). WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-W748. (Pubitemid 44530021)